Tubeless Insulin Pump Market By Product Type (Wearable Insulin Pumps, Implantable Insulin Pumps), By Components (Pod/Patch, Remote, Others), By Technology (Continuous Glucose Monitoring (CGM) Integrated Pumps, Standard Tubeless Pumps), By Distribution Channel (Hospitals, Pharmacies, E-Commerce, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Tubeless Insulin Pump market accounted for USD 2.15 Billion in 2024 and is expected to reach USD 21.7 Billion by 2035, growing at a CAGR of around 23.4% between 2025 and 2035. A tubeless insulin pump is one of the various types of insulin delivery systems specially designed for diabetics, not having an external tube. These pumps have come to be known as pods or patches and can be fixed directly to the skin, providing continuous subcutaneous insulin infusion (CSII) for better convenience and comfort for the users. The drivers include the increasing incidence of diabetes, especially type 1 diabetes. There is also a growing need for more patients to have effective ways to control their insulin levels. Improved technologies have enabled the integration of continuous glucose monitors with the automatic adjustment of insulin to optimize patient care. This tubeless insulin pump market is therefore driven by a rapid increase in demand by patients who prefer less obtrusive and more user-friendly devices.

Report Scope:

Market Dynamics

Growing Demand for Insulin Delivery Systems Due to Rising Diabetes Incidence

The demand for insulin delivery systems is considerably on the rise due to the rising incidence of diabetes across the globe, especially type 1. According to the IDF, the absolute number of adults with diabetes increased to around 537 million in 2021. This alarming increase demands diabetes management solutions that are quite effective. In that direction, tubeless insulin pumps are advantageous to patients for convenience and flexibility, while ensuring tight adherence to treatment.

The latest research in the Journal of Diabetes Science and Technology indicated that advanced methods of insulin delivery do enhance glycemic control and reduce complications associated with poorly managed diabetes. Furthermore, growing knowledge among patients about care and management options increases the demand for advanced systems meeting individual lifestyle needs to drive further market growth.

Technological Innovations Enhancing User Experience in Tubeless Insulin Pumps

Technological advancements in tubeless insulin pumps are one of the driving factors that enhance the user experience and lead to significantly improved management of diabetes. Smart dosing algorithms, integration with continuous glucose monitoring (CGM) systems, and connectivity with application platforms provide for real-time correction and more efficient insulin delivery. The American Diabetes Association has documented up to a 20% improvement in glycemic control when using advanced insulin delivery systems, such as tubeless pumps, compared with traditional methods. Users of integrated systems also experienced a 50% reduction in severe hypoglycemic events based on the findings of one study published in the Journal of Diabetes Research.

The integration of artificial intelligence in tubeless insulin pumps is likely to further optimize insulin delivery based on the patterns of individual users, thus increasing their effectiveness. Increasing innovation would likely drive future growth in the global market for tubeless insulin pumps as the continued technological advancement presents continuous evolutions in this potential.

Risks of Diabetic Ketoacidosis Hindering Growth of the Tubeless Insulin Pump Market

One of the majors restrains for the tubeless insulin pump market is increasing incidence of diabetic ketoacidosis, or DKA, among patients. The chances for developing DKA are high in patients who have failed pumps because the pump can fail in so many ways: it may drain all the batteries; become exposed to heat that makes the insulin inactive; or the reservoir can empty. These events can, therefore lead to catheter kinks that do not allow insulin to reach the body properly or seep out of the pores thus resulting in complications such as skin infections.

A study published on PubMed Central in February 2021 acknowledged this issue and found that, contrary to popular belief that insulin pumps had fewer instances of DKA than injections. The AHRQ conducted a retrospective cohort study of hospitalizations among patients aged 18 years and older who were diagnosed with type 1 diabetes. The patients used either a pump or injections for insulin. Of the 58,260 hospitalizations analyzed, 30,672 received insulin via injections, while 7,850 used pumps. The study concluded that compared with injections, insulin pumps presented no reduced incidence of DKA and called for careful management and monitoring of the functionality of pumps to minimize this risk.

Growing Focus on Preventative Healthcare Boosting Demand for Advanced Insulin Delivery Systems

This is a major potential application for advanced insulin delivery systems which incorporate tubeless insulin pumps. Their benefits can capitalize on the rising theme of preventive healthcare to address chronic diseases such as diabetes. The CDC states that one in ten Americans suffer from diabetes, and this figure does not count the rest who are likely to develop it. This has been accompanied by increased investments in diabetes education and management programs. Research has shown that effective management of diabetes is able to decrease healthcare costs by 50% through reduced hospital admissions and complications.

Advances in systems for the administration of insulin will help improve the adherence of patients to treatment plans. The American Diabetes Association refers to a report to this effect. With increased awareness for proper preventive care, more patients as well as healthcare providers are likely to seek advanced forms of insulin delivery solutions that would make possible better glycemic control and overall health, further driving market growth for tubeless insulin pumps.

Sustainability Initiatives in Tubeless Insulin Pumps to Attract Eco-Conscious Consumers

In the tubeless insulin pump market, sustainability initiatives will be a great opportunity for attracting the number of environmentally conscious consumers who are growing day by day. As concerns about environmental issues are rapidly increasing, many patients and healthcare providers are increasingly looking into sustainable products. Nielsen stated that 73% of millennial respondents are willing to pay more for sustainable products this has been the latest trend in the market as most customers prefer green solutions.

As a result, manufacturers are actively developing recyclable or biodegradable components for insulin pumps to minimize environmental damage. WHO research has been done to focus on the importance of green health care in reducing waste and promoting healthy surroundings. Regulatory authorities are also motivating greener technologies in medical devices. Thus, if the sustainability requirements are matched with the product offerings by those companies, then they will be in a position to fulfill the demand of consumers as well as strengthen their image as a brand for their growth in the tubeless insulin pump market.

Industry Experts Opinion

“One of the major goals of diabetes care is to help patients manage their blood glucose so well that they never have to visit an emergency room for diabetic ketoacidosis, a deadly complication of diabetes,”

• Basu, senior scientist in the UAB Comprehensive Diabetes Center

Segment Analysis

Based on Product Type, the tubeless insulin pump market can be divided into Wearable Insulin Pumps and Implantable Insulin Pumps. The wearable insulin pumps allow patients to move freely and live normally as the injection pump is not visually noticed. On the other hand, implantable pumps provide constant infusion with minimum external interference; therefore, these cater to different patient needs and preferences.

Based on Technology, the tubeless insulin pump market segmented into two categories, Continuous Glucose Monitoring (CGM) Integrated Pumps and Standard Tubeless Pumps. The integrated pumps with glucose CGM help monitor real-time glucose levels and automated delivery of insulin, which increases patient management. Standard tubeless pumps help in the delivery of insulin without the integration complexities and are hence simpler for patients to use as a solution. 

Regional Analysis

The North American market is one of the strongest markets due to a significant prevalence of diabetes and more developed healthcare infrastructure. The United States is a significant share, with nearly 38.4 million Americans having been diagnosed with diabetes according to the Centers for Disease Control and Prevention (CDC). This increased patient population is further driving demand for new insulin delivery solutions. The region-bound research and developments provide high-tech products. Diabetes care and preventive care have developed a growing interest, which boosts the market growth. Reimbursement policies also seem to be favorable, and a rising awareness of the benefits associated with insulin pumps further increases the adoption of the tubeless system. The North America region is considered a prime marketplace for the global tubeless pump market.

The Asia Pacific tubeless insulin pump market is growing at a very healthy rate due to an ever-increasing prevalence of diabetes and an improved healthcare infrastructure in the region. Countries like China and India are witnessing a significant increase in diabetes patients, estimated at over 141 million in China alone. This increases the demand for effective insulin delivery solutions. In addition, the ease of use, reliability, and accessibility of new insulin pumps are making them available to more patients, which further expands the market. In addition to quality of life from proper management and education, people today are also getting inclined towards better delivery systems. Moreover, government backing through numerous diabetes care schemes is providing a boost to the growth of the market, and Asia Pacific will prove to be a huge potential area for future growth of the tubeless insulin pump market.  

Competitive Landscape

Leading players among the companies that are dominating the market include Medtronic, Insulet Corporation, Tandem Diabetes Care, Roche Diabetes Care, and Abbott Laboratories, these companies are innovating and collaborating for better performance. For example, Medtronic is upgrading the MiniMed series, and the latest is smart technology integration while Insulet has expanded its Omnipod system and recently teamed up with firms in the tech industry to upgrade user experience.

Roche is looking to establish a connected ecosystem to help the patient with diabetes self-manage their condition, partnering with startups that can augment the digital solutions. Abbott is well-positioned on the innovative insulin delivery side in combining emerging pump technologies with its Freestyle Libre system. All this activity through mutual cooperation and cutting-edge innovation is changing diabetes care.

Tubeless Insulin Pump Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In April 2023, the FDA approved the Medtronic MiniMed™ 780G System, the first insulin pump with meal detection technology. This innovative device features 5-minute auto corrections, enhancing real-time insulin delivery for better diabetes management.
• In February 2024, Tandem Diabetes Care, Inc. unveiled Tandem Mobi in the U.S., featuring the smallest and most durable insulin delivery system on the market. This cutting-edge device aims to improve user convenience and flexibility in managing diabetes.

Report Coverage:

By Product Type

• Wearable Insulin Pumps
• Implantable Insulin Pumps

By Components

• Pod/Patch
• Remote
• Others

By Technology

• Continuous Glucose Monitoring (CGM) Integrated Pumps
• Standard Tubeless Pumps

Distribution Channel

• Hospitals
• Pharmacies
• E-Commerce
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Medtronic plc
• Insulet Corporation
• Tandem Diabetes Care, Inc.
• Roche Diabetes Care
• Abbott Laboratories
• Novo Nordisk
• Sanofi
• Ypsomed AG
• Ascensia Diabetes Care
• Becton, Dickinson and Company (BD)
• Eli Lilly and Company
• Fresenius Kabi
• Bigfoot Biomedical
• Diabeloop
• CureDM

Frequently Asked Questions (FAQs)